

Personalized treatment

- Improve a patient's outcome
- Make better clinical decisions

Radiomics



Radiomics on cone-beam CT images



Janita van Timmeren
(janita.vantimmeren@maastro.nl)
Maastro Clinic
Maastricht University
The Netherlands

Cone-beam CT

CBCT ●

- Prior to radiotherapy
 - Weekly / daily
- Follow treatment

Conventional CT vs. kV cone-beam CT




Cone-beam CT radiomics?

"Delta"
radiomics

Challenges:


- Lower image quality
- Sensitive to artefacts

Radiomics? Quantitative and independent method to monitor response to treatment!



Radiomics signature

- Cox regression hazards model based on four radiomic features



Aerts, H. J. W. L. *et al.* Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat. Commun.* 5:4006 doi: 10.1038/ncomms5006 (2014)

Radiomics signature

- Related to proliferation
- Able to predict outcome for lung cancer and head & neck cancer using CT images
- Prognostic/predictive value of cone-beam CT images for lung cancer patients?

Methods

216 patients with stage II-III non-small cell lung cancer (NSCLC)

4 radiomic features derived from:

- Treatment planning CT (**CT₁**)
- Cone-beam CT prior to the first fraction (**CBCT-fx₁**)
- Cone-beam CT prior to the second fraction (**CBCT-fx₂**)

Correlation and stability

Compare 4 radiomic features

Correlation: Planning CT (CT_1) vs.
cone-beam CT fraction 1 ($CBCT-fx_1$)

Stability: Cone-beam CT fraction 1 ($CBCT-fx_1$) vs.
cone-beam CT fraction 2 ($CBCT-fx_2$)

Intraclass correlation coefficient (ICC)

Model validation

Prior to model validation:

- Relationship between CT and cone-beam CT?
- Linear regression → derive correction factor
- Based on 20 patients

Validate radiomic signature on cone-beam CT:

- Compare Kaplan-Meier curves
- Harrell's concordance index (c-index)

Radiomic signature


ICC ●

<i>Feature name</i>	pCT vs. CBCT-FX ₁	CBCT-FX ₁ vs. CBCT-FX ₂
Stats – Energy	0.92	0.91
RLGL – Gray Level Nonuniformity	0.88	0.92
Wavelet – HLH RLGL Gray Level Nonuniformity	0.86	0.91
Shape – Compactness	0.97	0.98

Correction factor

Prior to
model
validation

Example for one feature:



Correction factor


Prior to
model
validation

<i>Feature name</i>	<i>Slope</i>	<i>SE</i>	<i>R²</i>
Stats – Energy	1.26	0.02	1.00
RLGL – Gray Level Nonuniformity	0.67	0.01	1.00
Wavelet – HLH RLGL Gray Level Nonuniformity	0.65	0.02	0.98
Shape – Compactness	1.03	0.02	0.99

Kaplan-Meier curves

Model validation

$p = 0.021$ (pCT) and $p = 0.0089$ (CBCT-FX1)



Harrell's concordance-index

c-index

0.5 → no discrimination

1.0 → perfect discrimination

pCT: $c\text{-index} = 0.63$

(95% CI [0.57 – 0.68], $p < 0.0001$)

CBCT-FX1: $c\text{-index} = 0.64$

(95% CI [0.57 – 0.71], $p < 0.0001$)

Previous external validation:

$c\text{-index}$ between 0.63 and 0.65 for CT images

Leijenaar RT. et al. External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. *Acta Oncol.* 2015 Oct;54(9):1423-9.

Discussion

Challenges:

- Sensitivity to artefacts
- Limited field of view
- Differences between (reconstruction) settings → standardization needed

CBCT “Delta-radiomics”

Potential

Results show great potential for “Delta-radiomics”

Future → Improve prognostic value of CBCT imaging using delta-features

- Better treatment decisions
- Improved outcome

Acknowledgements

Maastrro Clinic

Ralph Leijenaar
Wouter van Elmpt
Philippe Lambin

Thank you for your attention

Janita van Timmeren
(janita.vantimmeren@maastro.nl)
Maastro Clinic
Maastricht University
The Netherlands